heterozygous familial hypercholesterolaemia
Cardiovascular · 2005–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alirocumab Treatment of familial heterozygous hypercholesterolaemia (he-FH) and non-familial hypercholesterolaemia (non-FH), and prevention of cardiovascular events. | Mar 2023 | Recommended | input received |
| alirocumab Treatment of heterozygous familial hypercholesterolaemia (he-FH) with high cardiovascular risk (patients with atherosclerotic disease and/or very high LDL… | Mar 2019 | Recommended with restriction | 6 individuals Familial Hypercholesterolaemia Family Support Group |
| evolocumab Treatment of heterozygous familial hypercholesterolaemia (with atherosclerotic disease or very high LDL-c levels) and non-familial hypercholesterolaemia with… | Nov 2017 | Deferred | 18 individuals |
| alirocumab Heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease in patients with inadequate control on statins and… | Nov 2017 | Not recommended | 13 individuals |
| ezetimibe; ezetimibe with simvastatin Co-administration with a statin in patients with inadequately controlled cholesterol levels and coronary heart disease, diabetes mellitus, peripheral vascular… | Nov 2005 | Recommended with restriction | no section in document |
| ezetimibe; ezetimibe with simvastatin Addition of ezetimibe and ezetimibe with simvastatin to the current listing for co-administration with statins in patients with inadequately controlled… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Familial Hypercholesterolaemia Family Support Group
What the PBS pays
$178M in government benefit over 2024–25, across 7,236,754 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ezetimibe; ezetimibe with simvastatin | $65M |
| evolocumab | $63.2M |
| ezetimibe | $49.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.